Cergy, France

Jean-Claude Hardy

This inventor holds 12 USPTO granted patents. Top assignees: Rhone-Poulenc Rorer S.a., Aventis Pharma S.a., Rhone-Poulenc Sante. Active years: 1990-2004.


% Patents Active = 75.0

Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 71(Granted Patents)


Location History:

  • Cergy, FR (1990)
  • Cergy Pontoise, FR (1991)
  • Cergy-Saint-Christophe, FR (1999 - 2004)

Company Filing History:


Years Active: 1990-2004

Loading Chart...
12 patents (USPTO):Explore Patents

Title: The Innovative Journey of Jean-Claude Hardy

Introduction

Jean-Claude Hardy is a prominent inventor based in Cergy Saint Christophe, France. He has made significant contributions to the field of medicinal chemistry, holding a total of 12 patents. His work primarily focuses on the development of novel compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents are innovative methods involving thiazolobenzoheterocycles. These patents include "Methods of using thiazolobenzoheterocycles" and "Thiazolobenzoheterocycles, their preparation and medicaments containing them." These inventions highlight his commitment to advancing medicinal chemistry and improving healthcare solutions.

Career Highlights

Throughout his career, Jean-Claude Hardy has worked with notable companies such as Rhône-Poulenc Rorer S.A. and Aventis Pharma S.A. His experience in these organizations has allowed him to develop and refine his expertise in pharmaceutical research and development.

Collaborations

Jean-Claude has collaborated with esteemed colleagues, including Patrick Nemecek and Jean-Claude Aloup. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Jean-Claude Hardy's contributions to the field of medicinal chemistry through his patents and collaborations demonstrate his dedication to innovation. His work continues to impact the pharmaceutical industry positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…